IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re the Ap	plication of:	
DEN	G et al.	
Serial No.: 1	10/612,779	<u>INFORMATION</u> <u>DISCLOSURE STATEMENT</u>
Filed: July 1	, 2003	DISCLOSURE STATEMENT
Atty. File No	o.: 3161-18-2	CERTIFICATE OF MAILING
PRO	OCESS AND MATERIALS FOR ) ODUCTION OF GLUCOSAMINE ) O N-ACETYL GLUCOSAMINE"	I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO THE COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 ON SHERIDAN ROSS P.C.  BY:
P.O. Box 14:	er for Patents	1 /
Dear Sir:		
	references cited on attached Form PT	O-1449 are being called to the attention of the
Examiner.		
⊠	Copies of the cited non-patent and/o	or foreign references are enclosed herewith.
	Copies of the cited U.S. patents and	Vor patent applications are enclosed herewith.
	Copies of the cited U.S. patents/pate	ent application publications are not enclosed in
accordance v	with the waiver dated July 11, 2003, v	whereby patent applications filed after June 30,
2003 and into	ernational applications that have entere	ed the national stage under 35 U.S.C. § 371 after
June 30, 200	3 need not submit copies of U.S. pater	nts and U.S. patent application publications.
	Copies of the cited references are no	ot enclosed, in accordance with 37 CFR 1.98(d),
because the r	references were cited by or submitted to	o the U.S. Patent and Trademark Office in prior
application S	Serial No filed	, which is relied upon for an earlier
filing date ur	nder 35 U.S.C. § 120.	
	To the best of applicants' belief, the p	pertinence of the foreign-language references are
believed to b	e summarized in the attached English	abstracts and in the figures, although applicants
do not neces	sarily youch for the accuracy of the tra	anslation

	Examiner's attention	is drawn to	the following	co-pending	applications,	copies of
which have be	een or are being submit	ted:				
	Serial No.		filed			

Submission of the above information is not intended as an admission that any item is citable under the statutes or rules to support a rejection, that any item disclosed represents analogous art, or that those skilled in the art would refer to or recognize the pertinence of any reference without the benefit of hindsight, nor should an inference be drawn as to the pertinence of the references based on the order in which they are presented. Submission of this statement should not be taken as an indication that a search has been conducted, or that no better art exists.

It is respectfully requested that the cited information be expressly considered during the prosecution of this application and the references made of record therein.

## **FEES**

Ø	37 CFR 1.97(b): No fee is believed due in connection with this submission, because the information disclosure statement submitted herewith is satisfies one of the following conditions ("X" indicates satisfaction):						
	Within three months of the filing date of a national application other than a continued prosecution application under 37 CFR 1.53(d), or						
	Within three months of the date of entry into the national stage of an international application as set forth in 37 CFR 1.491 or						
	Before the mailing date of a first Office Action on the merits, or						
	Before the mailing of a first Office action after the filing of a request for continued examination under 37 CFR 1.114.						
	Although no fee is believed due, if any fee is deemed due in connection with this submission, please charge such fee to Deposit Account 19-1970.						
	37 CFR 1.97(c): The information disclosure statement transmitted herewith is being filed after all the above conditions (37 CFR 1.97(b)), but before the mailing date of one of the following conditions:  (1) a final action under 37 CFR 1.113 or  (2) a notice of allowance under 37 CFR 1.311, or  (3) an action that otherwise closes prosecution in the application.  This Information Disclosure Statement is accompanied by:						
	A Certification (below) as specified by 37 CFR 1.97(e). Although no fee is believed due, if any fee is deemed due in connection with this submission, please charge such fee to Deposit Account 19-1970.  OR						
	Please charge Deposit Account 19-1970 in the amount of \$180.00 for the fee set forth in 37 CFR 1.17(p) for submission of an information disclosure statement. Please credit any overpayment or charge any underpayment to Deposit Account 19-1970.						
	37 CFR 1.97(d): This Information Disclosure Statement is being submitted after the period specified in 37 CFR 1.97(c)  This information Disclosure Statement includes a Certification (below) as specified by 37 CFR 1.97(e)  AND						
	Applicants hereby requests consideration of the reference(s) disclosed herein. Please charge Deposit Account 19-1970 in the amount of \$180.00 under 37 CFR 1.17(p). Please credit any overpayment or charge any underpayment to Deposit Account 19-1970. Election to pay the fee should not be taken as an indication that applican cannot execute a certification.						

Certification (37 CFR 1.97(e))
(Applicable only if checked)

The undersigned certifies that:

Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. 37 CFR 1.97(e)(1).

A copy of the communication from the foreign patent office is enclosed.

OR

No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this statement. 37 CFR 1.97(e)(2).

Respectfully submitted,

SHERIDAN ROSS P.C.

By:

Angela Dallas Sebor Registration No. 42,460 1560 Broadway, Suite 1200

Denver, CO 80202-5141

(303) 863-9700

Date: 4lbruary 2, 2005

•			15410			
	1440A (DTO		Complete if Known			
Sub	stitute for form	1449APTO	BOD MOS RE	Application Number	10/612,779	
IN	FORMAT	CION DESC	LOSURE	Filing Date	July 1, 2003	
SI	ATEME	NT BY AR	BLIGANT	First Named Inventor	Deng	
•	/ \ 1 = 101 = 1		Chief Parent	Art Unit		
				Examiner Name		
Sheet	1	of	1	Attorney Docket Number	3161-18-2	

	U.S. PATENT DOCUMENTS									
Examiner Initials*	Cite No.¹	Document Number Number-kind Code <sup>2 (Akrosn)</sup>	Publication Date MM-DD-YYYY		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear					
		US-								
		US-								
		US-								
		US-								
		US-								
		US-	****							
		US-								
		US-								
		US-								
		US-								

				FOREI	<b>GN PATENT DO</b>	CUMENTS		
Examiner Initials*	Cite No.1	Country C		eign Patent Document  Number*: Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁵
		PCT	-	WO 97/31121	08/28/1997	Univ. British Columbia		
			<u> </u> -					Γ
			<u> -</u>					Π
			-					Ī
			<u> -</u> _					
			-					
			-					

		OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)
Examiner Initials*	Cite No.1	

Examiner Sigature	Date Considered		
- garage	Odrisiacica	L	

<sup>\*</sup>EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.